NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP 50 Pharmas  «  1  2  3  4  5  » 
found files: 188
Johnson & Johnson »20/11/2007 [Company watch]
Johnson & Johnson to Hold 70% of Xi'an-Janssen

Johnson & Johnson Ltd. (NYSE: JNJ), plans to buy more shares in Xi'an-Janssen Pharmaceutical Ltd. from the latter's Chinese shareholders, according to an insider from the pharmaceutical joint venture on November 20, 2007. The buyer is in negotiations with three Chinese shareholders to acquire a 17.2% stake in the joint venture on the base that the equity structure of the sellers would not change. The acquisition has been approved by China's Ministry of Commerce, said the insider. The deal might enlarge Johnson & Johnson's holding in Xi'an-Janssen to 70% from currently 52%. Johnson & Johnson (China) Investment has recently acquired 1.8% of Xi'an-Janssen for CNY 78 million from Shaanxi Hanjiang Pharmaceutical Group Co., Ltd. The other three Chinese shareholders are Shaanxi Pharmaceutical Industry Corporation with a 33.6% stake; China National Pharmaceutical Industry Corporation 5.76%; and China National Pharmaceutical Foreign Trade Corporation 3.84%. Xi'an-Janssen was jointly set up by Belgium-based Janssen Pharmaceutica NV of Johnson & Johnson and the four Chinese state-owned companies in October 1985....   more»


GlaxoSmithKline »13/12/2007 [Company watch]
GSK says will spend $100m in China R&D

Hong Kong, Dec 13, 2007: British pharma giant GlaxoSmithKline (GSK) has said it will invest $100 million by 2008 end to start a neuroscience research center in Shanghai. According to a UK business paper the Chinese center will become an important base for GSK to develop global drug. GSK’s Chairman of R&D, Moncef Slaoui told the paper that the Shanghai center will be a one stop shop doing research on all neurodegenerative diseases such as Alzheimer's, Parkinson's disease and multiple sclerosis. The paper quoted him as saying, "For us, China is not about outsourcing and cheap labor. We don't want to give them the crumbs. It's about different science. We will link our fate to their fate. Within five to ten years we will be moving from 'made in China' to discovered in China." Increasingly global pharma companies are looking at China and India both as ready market and a place to do high end research due to their huge population and young scientists and professionals. GSK zeroed in on China as it was looking at the next seedbed for future discoveries. Slaoui said, "qualitatively and numerically, China came out on top, especially in oncology and neurology.”...   more»


Merck & Co »27/01/2008 [Industry news]
Taiwan to get Merck Asia Technology Training Center

American pharma giant Merck has said it will base its Asia Technology Training Center in Taiwan. Merck said it was starting the center in Taiwan due to its strong support for pharma companies. Last July, Taiwan promulgated the statute for developing biotechnological new pharmaceuticals enterprises which helps pharma and biotechnology firms to have a strong research base in the island. Wu Shuh-min, chairman Development Center of Biotechnology said the new effort by Taiwan has improved its image as an ideal investment destination for pharmaceuticals and biotechnology. Wu also said the center will work with Merck to boost cooperation...   more»


Baxter International »25/01/2008 [Company watch]
Baxter International outbids Double-Crane, takes full ownership of Baxter Health

On January 25 Baxter International (NYSE:BAX) 25 successfully outbid Beijing Double-Crane Pharmaceutical (SHA: 600062) for the remaining 40% of its Shanghai JV. The stake, previously owned by Worldbest Treeful Pharmaceutical, was put up for auction by the Bank of China after Worldbest Treeful became financially distressed. Baxter International will pay RMB 180 million in a deal that makes Baxter Healthcare (Shanghai) a wholly-owned foreign enterprise. Beijing Double-Crane Pharmaceutical previously announced that it would participate in the auction, hoping to integrate Baxter's infusion products into its business. Baxter Healthcare (Shanghai) was established as a joint venture (JV) between Baxter International and Worldbest Treeful. Worldbest Treeful originally invested USD 4.8 million for the 40% stake in the JV. Baxter Healthcare (Shanghai) is headquartered in Shanghai and is focused on drug infusions, renal products, biotechnology, and anesthesia....   more»


Baxter International »29/01/2008 [Company watch]
Baxter Achieves Record Sales and Earnings for Full-Year 2007

Accelerating R&D and Business Development In 2007, Baxter accelerated its investment in R&D to a record level of $760 million, representing an increase of 24 percent over the prior year. The company obtained approval or launched more than a dozen new products and therapies during the year, and achieved a number of important business and scientific milestones....   more»


AstraZeneca »29/02/2008 [Company watch]
Year End Results for AStra Zeneca - Increase to China Investment

AstraZeneca to increase China investment According to AstraZeneca's annual report released February 26, the company's global net income for 2007 dropped 7.2% to USD 5.63 billion, while sales in China rose by 25% to USD 500 million. The company will increase its China investment with the construction of the AstraZeneca Industrial Park (translated by GB). The park will include facilities for company management, research and development, and staff training. Brief view of Results: Turnover (up) $29,559 Millions R & D Spend (up) $5162 Millions Net Profit B T (down) $7,983 Millions...   more»


Johnson & Johnson »28/02/2008 [Company watch]
Johnson & Johnson to establish cancer center in Tianjin

Johnson & Johnson signed a letter of intent with the Tianjin Medical University Cancer Institute and Hospital on February 26 to finance the construction of the Tianjin - Johnson Cancer Cooperation Development Centre in the Tiajin Binhai New Area. Tianjin Medical University's Cancer Institute and Hospital is a leading research base for cancer prevention and treatment, housing one of the most advanced tumor tissue banks in China....   more»


Johnson & Johnson »20/02/2008 [Company watch]
Johnson & Johnson 2007 Results

Revenues (up) $61,100 Millions Net Profit (down) $ 10,576 millions R & D Spend $ 8,487 Millions...   more»


Baxter International »29/02/2008 [Company watch]
Baxter heparin scare linked to Chinese maker, US FDA also accused

Another US drug scare has been linked to Chinese manufacturers. At the center of the scandal is Baxter's heparin product, production of which was halted February 11 in the US after hundreds of reports of side effects and four deaths were linked to the product. According to news reports, Baxter sources the drug's API from a US supplier who, in addition to a US plant, also operates a plant in China. Further investigation revealed that the US FDA never inspected the Chinese facility, a mandatory step for any manufacturer supplying drug ingredients to the US. Though, like the recent RU 486 scare, there is no evidence tying the Chinese plant to the adverse reactions, media accounts have turned an accusing eye (again) on Chinese drug manufacturers; this time, however, the US FDA shares the glare. One US congressman has even called for the resignation of FDA chief von Eschenbach. The incident has had far reaching effects on the US healthcare market as well. Baxter manufactures approximately 50% of heparin sodium used in the US, and the recent halt to production has the US FDA encouraging other makers, such as APP Pharmaceuticals (NASDAQ: APPX), to increase production. The stock price of APP Pharmaceuticals risen as much as 8% in response....   more»


Novartis »28/02/2008 [Company watch]
Novartis annual results reports significant China growth in 2007

Novartis announced 2007 financial results on February 28. In 2007, sales for Novartis China rose by 25% to RMB 2.58 billion. Beijing Norvatis Pharmaceutical's sales totaled RMB 2.0 billion, 27% year over year growth. Global results T/O $ 38,100 millions Net Profit $ 6.500millions R & D Spend $6,400 millions According to the report, sales of the anti hypertension drugs Diovan and Lotensin both increased substantially; sales of Lotensin alone exceeded RMB 400 million. Four other products, Voltaren, Glivec, Sandimmun, and Miacalive, also achieved sales of more than RMB 100 million in 2007. Sales of Novartis vaccines were greater than RMB 50 million. The company predicts that it will see growth of more than 20% in 2008. Novartis also announced that it has begun construction of a new R&D center in Shanghai and expects to have Suzhou facility production ready in 2008....   more»


Pfizer »08/03/2008 [Company watch]
Pfizer plans to cut costs and expand in China

Pfizer says it is planning to outsource more drug manufacture, to lower costs ahead of the generic competition for its cholesterol drug Lipitor, and to continue expansion broadly in China. Lipitor's patent expires at the end of 2011. At the same time Pfizer reaffirmed its profit forecast for 2008 with anticipated revenue of $48.08 Billions....   more»


Bayer »05/03/2008 [Company watch]
Bayer expects to be China's biggest drug seller within months

The Company's Asia unit said it expects to be China's biggest drug seler thanks to its treatments for diabetes and blood pressure. In 2007 sales in China grew 47% to $1.3billion making up about a third of its revenues in Asia (excluding Japan)....   more»


Wyeth »10/03/2008 [Company watch]
Wyeth to build world's largest nutritional manufacturing plant in Chin

US Healthcare company Wyeth announced it will invest 2 Billion Yua ($280 Billion Dollars) in the eastern province of Jiangsu to establish a nutritional products manufacturing facility. The new plant which will mainly produce infant milk powder and other nutritional products would be one of the world's largest nutritional product factories when completed. The plant is expected to open in 2010 and output is expected to be sold mainly, for the domestic market....   more»


AstraZeneca »19/03/2008 [Company watch]
Astra Zeneca's Expansion

Expanding the presence of AstraZeneca (AZN) in the Asia-Pacific region in general and China specifically is a priority for AstraZeneca, according to John Ramsey, AstraZeneca’s Vice President for Global Development. Ramsey made the remarks in an interview with EView Week. Ramsey stressed that AstraZeneca is interested in developing drugs that address the needs of China’s population. Toward that end, AstraZeneca has established its Innovation Center China [ICC], which began operations in 2007 and establishes relationships with China’s universities and medical centers. Because of the company’s emphasis on China’s needs, Ramsey can boast that AstraZeneca’s $100 million investment in China (spread over two to three years) is the largest of any biopharma that is focused on China’s diseases. The ICC will concentrate on cancer, seeking to learn more about liver cancer, gastric cancer, lung cancer and pre-menopausal breast cancer. It will study the causes of the disease, define biomarkers and identify new targets for innovative drugs. The growing China market for drugs is one reason that AstraZeneca chose to concentrate in China. But just as important was its pool of scientific talent and unique medical needs. Although AstraZeneca China’s motto is “In China, For China,” the staff at ICC has the ability to work with AstraZeneca scientists from around the world. So far, the ICC has put on its staff 40 researchers, 40% of them with PhDs. The target is to hire 60 scientists. AstraZeneca China currently has a total workforce of 2,500....   more»


Boehringer Ingellheim »01/04/2008 [Company watch]
Boehringer Ingleheim Chinese subsidiary 2007 results

The China subsidiary of Boehringer Ingelheim, Shanghai Pharmaceuticals, said its 2007 revenues rose 46% to 697 million RMB ($95 million). BI China expects that its revenues will increase over the next five years until they reach 2.3 billion RMB ($327 million) in 2012. BI China implied the reason behind its year-over-year increase was a distribution deal that it signed in 2006 with the state-owned pharmaceutical giant Sinopharm...   more»


Sanofi-Aventis »03/04/2008 [Company watch]
Sanofi seeks partnerships in China

Dr. Marc Cuzel, head of R&D for Sanofi-Aventis , said that Sanofi would seek to establish half a dozen research partnerships with China universities and state-sponsored research institutions . This initiative will take the place of building its own research center in China. Sanofi believes that China is a good place to do research, but it already has so much innovation, Sanofi believes partnerships are a better way of taking advantage of China’s research capabilities. Sanofi will seek research in cancer and rheumatoid arthritis, he said....   more»


AstraZeneca »31/03/2008 [Company watch]
China SFDA gets Tough and AZ affected

China's drug regulatory authority is finally responding to curb its damaged reputation by urging its local authorities to take a more proactive role in stemming what is fast becoming a global heparin contamination, sparked by material sourced in the country. According to Chinese media reports, the State Food and Drug Administration (SFDA) issued a message on its website urging its regional offices to boost their supervision of the production methods of heparin manufacturers in their locality. The watchdog has also urged heparin producers to source their raw heparin from registered suppliers only, and issued a plea to heparin manufacturers to ensure they are producing the material in accordance with the approved standards. In addition, the SFDA warned manufacturers that they must take the initiative to closely follow the clinical effects of their products that are on the market and if any problems are linked back to their manufacturing facilities, they must halt production immediately and recall any implicated products from the market....   more»


Wyeth »15/04/2008 [Company watch]
Wyeth complains about slow approval process in China

Wyeth (NYSE: WYE) told Interfax that it would not create an R&D center in China because the SFDA takes too long to approve initial clinical trials (see article). The IND process in the US and Europe involves only a 30-day waiting period, but the same process in China can be nine months or more. On the other hand, even though it will not establish an R&D center in China, Wyeth said it would make several moves to increase its use of China’s R&D expertise....   more»


Novo Nordisk »28/04/2008
Novo Nordisk donation aids Chinese pharmaceutical development and WHO efforts to combat neglected diseases

Novo Nordisk today announced a scientific collaboration that will benefit both Chinese pharmaceutical development and WHO efforts to combat neglected diseases. Effective 28 April 2008, Novo Nordisk will donate a licence to its small molecule compound library to the National Center for Drug Screening (NCDS) affiliated to Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The centre will use the library – both the actual compounds and an associated database – for screening activities to identify new drug candidates for infectious tropical diseases that affect people in poor countries. The World Health Organization-based Special Programme for Research and Training in Tropical Diseases (TDR) will select targets and screens to support the identification of new drug candidates or leads for infectious tropical diseases, including malaria, tuberculosis, African sleeping sickness, dengue, Chagas disease, leishmaniasis, schistosomiasis, filariasis, onchocerciasis and soil-transmitted helminths. It will also bring in young scientists from developing countries, especially Africa, to be trained at the institute....   more»


GlaxoSmithKline »03/05/2008 [Company watch]
GSK reorganiseis to focus on emerging markets

GlaxoSmithKline (NYSE: GSK) has reorganized its corporate structure to put an increased focus on emerging markets. A new management group was given the charge of increasing business in the Emerging Markets, defined as China, Russia, Brazil, India and the Middle East. Even though the countries are not closely linked geographically, GSK believes the structure of the pharmaceutical markets in each nation is very similar, allowing for a unified strategy. The move was taken because of the growth for pharmaceuticals expected in these countries....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.